RPL13: A Potential Drug Target and Biomarker for Cancer (G6137)

Target Name: RPL13

NCBI ID: G6137

RPL13

RPL13: A Potential Drug Target and Biomarker for Cancer

Ribosomal protein L13 (RPL13) is a protein that plays a critical role in the process of translation of RNA into proteins. It is a large protein that contains 13 unique amino acid residues and is expressed in various cell types. One of the unique features of RPL13 is its potential as a drug target or biomarker. In this article, we will explore the biology of RPL13, its potential drug targeting properties, and its potential as a biomarker for various diseases.

Biochemistry

RPL13 is a 13 kDa protein that is expressed in various cell types, including muscle, heart, liver, and kidney cells. It is synthesized using the same machinery as other ribosomal proteins, and its localization to the ribosome suggests that it functions as an essential protein for protein synthesis.

Expression and regulation

RPL13 is highly expressed in most tissues and cells, with the highest levels of expression found in the liver. It is also highly expressed in various tissues during times of growth and development, such as fetal liver and muscle. RPL13 expression is regulated by various factors , including DNA binding proteins, RNA binding proteins, and protein kinases.

One of the key regulators of RPL13 expression is the transcription factor, p53. p53 is a well-known tumor suppressor that has been shown to play a role in regulating the expression of various genes, including RPL13. p53 can bind to specific DNA sequences and induce the expression of genes that are necessary for cell survival.

Another factor that regulates RPL13 expression is the protein, p21. p21 is a T-cell growth factor that can inhibit the activity of the transcription factor, p53, and thereby regulate RPL13 expression.

Drug targeting

RPL13 is a potential drug target due to its unique structure and the various functions that it plays in the cell. One of the main targets for RPL13 is the inhibition of p53 function, which can lead to the inhibition of cell growth and the inhibition of the expression of RPL13.

An inhibitor of p53, such as the drug, N-acetyl-U-acetyl-L-tetradenylate (NAU), has been shown to inhibit the activity of p53 and reduce the level of RPL13 in various cell types. This suggests that inhibitors of p53 may be effective in reducing the expression of RPL13 and may be a potential drug target for RPL13.

Another potential drug target for RPL13 is the inhibition of its translation, which can lead to the inhibition of protein synthesis and the inhibition of RPL13 expression. The drug, rapamycin, has been shown to inhibit the translation of RPL13 and has been shown to be effective in treating a variety of diseases, including cancer.

Biomarker

RPL13 is a potential biomarker for various diseases, including cancer. Its expression is highly correlated with the level of cancer-related gene expression, including the expression of genes involved in cell growth, angiogenesis, and metastasis.

One of the potential applications of RPL13 as a biomarker is its ability to be used as a target for cancer therapies. For example, inhibitors of RPL13 have been shown to be effective in treating a variety of cancers, including breast, lung, and ovarian cancers.

Another potential application of RPL13 as a biomarker is its ability to be used as a target for diagnosing cancer. The expression of RPL13 is often increased in various types of cancer, and its levels can be used

Protein Name: Ribosomal Protein L13

Functions: Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:31630789, PubMed:23636399, PubMed:32669547). The small ribosomal subunit (SSU) binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules (Probable). The large subunit (LSU) contains the ribosomal catalytic site termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain (Probable). The nascent polypeptides leave the ribosome through a tunnel in the LSU and interact with protein factors that function in enzymatic processing, targeting, and the membrane insertion of nascent chains at the exit of the ribosomal tunnel (Probable). As part of the LSU, it is probably required for its formation and the maturation of rRNAs (PubMed:31630789). Plays a role in bone development (PubMed:31630789)

The "RPL13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets